Mucormycosis: A deadly black fungus infection among COVID-19 patients in India

被引：13

作者：

Choudhary, Naveen Kumar ^{[1
]}

Jain, Amit K. ^{[1
]}

Soni, Rupesh ^{[1
]}

Gahlot, Neha ^{[1
]}

机构：

[1] Mandsaur Univ, BR Nahata Coll Pharm, Mandsaur 458001, India

来源：

CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH | 2021年 / 12卷

关键词：

COVID-19; Mucormycosis; Black fungus; Hyperglycemia; Immunosuppressant; AMPHOTERICIN-B; INVASIVE PULMONARY; ZYGOMYCOSIS; DIAGNOSIS; RHIZOPUS; PERSPECTIVES; POSACONAZOLE; THERAPY; DISEASE;

D O I：

10.1016/j.cegh.2021.100900

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

After first phase of Covid-19, the second wave affects a lot to the Indians with mysterious fungal infection known as Mucormycosis. Here, we reviewed clinical pathogenesis, signs, symptoms and treatment against black fungus. The conclusion revealed that use of immunosuppressant to combat Covid-19 also increases the risk to get infected with mucormycosis. Patients with hyperglycemia, ketoacidosis, solid organ or bone marrow transplantion, liver cirrhosis, neutropenia are more susceptible to get attacked by Mucormycosis moulds. Early diagnosis, removal of predisposing factors, timely antifungal therapy with surgical removal of all infected tissues and adjunctive therapies are four major factors to eradicate Mucormycosis.

引用

页数：5

共 53 条

[51] Early Clinical and Laboratory Diagnosis of Invasive Pulmonary, Extrapulmonary, and Disseminated Mucormycosis (Zygomycosis) [J].